Screener
Abbott ABT Established Pharmaceuticals — Selling, general, and administrative
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
| (in millions) | Net Sales to External Customers / Three Months Ended June 30, 2026 | Net Sales to External Customers / Three Months Ended June 30, 2025 | Cost of Products Sold / Three Months Ended June 30, 2026 | Cost of Products Sold / Three Months Ended June 30, 2025 | Research and Development / Three Months Ended June 30, 2026 | Research and Development / Three Months Ended June 30, 2025 | Selling, General, and Administrative / Three Months Ended June 30, 2026 | Selling, General, and Administrative / Three Months Ended June 30, 2025 | Operating Earnings / Three Months Ended June 30, 2026 | Operating Earnings / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Established Pharmaceuticals | $1,499 | $1,383 | $(650) | $(631) | $(48) | $(43) | $(419) | $(363) | $382 | $346 |
| Nutritional Products | 2,144 | 2,212 | (1,148) | (1,155) | (54) | (54) | (574) | (585) | 368 | 418 |
| Diagnostic Products | 3,092 | 2,173 | (1,532) | (1,224) | (268) | (154) | (793) | (423) | 499 | 372 |
| Medical Devices | 5,853 | 5,369 | (1,925) | (1,758) | (470) | (430) | (1,489) | (1,385) | 1,969 | 1,796 |
| Total | $12,588 | $11,137 | $(5,255) | $(4,768) | $(840) | $(681) | $(3,275) | $(2,756) | $3,218 | $2,932 |
| Other | 5 | 5 | ||||||||
| Net sales | $12,593 | $11,142 | ||||||||
| Corporate functions and plan benefit costs | (45) | (65) |
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's established pharmaceuticals — selling, general, and administrative?
- Abbott (ABT) reported established pharmaceuticals — selling, general, and administrative of $419M in Q2 2026.
- How has Abbott's established pharmaceuticals — selling, general, and administrative changed year-over-year?
- Abbott's established pharmaceuticals — selling, general, and administrative increased by 15.4% year-over-year, from $363M to $419M.
- What is the long-term trend for Abbott's established pharmaceuticals — selling, general, and administrative?
- Over 3 years (2022 to 2025), Abbott's established pharmaceuticals — selling, general, and administrative has grown at a 2.0% compound annual growth rate (CAGR), from $1.37B to $1.46B.
- What does established pharmaceuticals — selling, general, and administrative mean?
- This metric includes all operating expenses related to the sales, marketing, and general administration of the established pharmaceuticals segment. It covers the costs of the sales force, promotional activities, and administrative overhead required to run the business. Monitoring this helps evaluate the operational leverage and efficiency of the segment's commercial organization.
Ask your AI about Abbott's established pharmaceuticals — selling, general, and administrative.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude